FDA OTC Monograph vs CPNP: What Importers File

Compare FDA OTC monograph and EU CPNP requirements for FDA CPNP whitening import compliance — GMP, documentation, and filing steps for importers.

FDA OTC Monograph vs CPNP: What Importers Must File for FDA CPNP Whitening Import Compliance

If you are sourcing professional whitening products for distribution in the United States or the European Union, your regulatory pathway is not a formality — it determines whether your shipment clears customs, whether your product can legally be sold, and whether your brand carries liability for a misclassified formula. FDA CPNP whitening import compliance as a paired concept means understanding two structurally different systems: the US treats hydrogen peroxide-based whitening products as OTC drugs; the EU treats most whitening products as cosmetics. The documentation burden, GMP standards, and pre-market obligations differ at every step.

Two Compliance Logics — One for Drugs, One for Cosmetics

In the US, whitening products making therapeutic claims — including claims about chemically altering tooth structure or killing oral bacteria — fall under FDA's OTC drug monograph framework. In the EU, most whitening products, including those formulated with hydrogen peroxide within permitted concentration limits, are regulated as cosmetics under Regulation (EC) No 1223/2009, with pre-market notification submitted through the Cosmetics Products Notification Portal (CPNP).

Importers who conflate these frameworks routinely stall at the border or face post-market enforcement action. The filing structure, the responsible parties, and the GMP expectations are distinct in each market. Treating one system's documentation as a proxy for the other is a compliance risk that experienced buyers eliminate before issuing a purchase order.

The FDA OTC Monograph Framework: What It Covers

The FDA OTC monograph system establishes the conditions under which an OTC drug can be legally marketed in the US without a new drug application. According to FDA, an OTC monograph defines the permitted active ingredients, their concentrations, approved uses, dosage forms, routes of administration, required labeling language, and applicable testing standards. For whitening products, this framework directly governs any formulation where a drug claim is made.

The CARES Act of 2020 reformed this system significantly. As documented by both FDA and the US Government Accountability Office, the Act replaced the prior notice-and-comment rulemaking process with a streamlined administrative order system. Industry can now petition for changes to monograph conditions through a formal OTC Monograph Order Request process. For importers, this means the regulatory text governing your product's active ingredient and labeling is established by administrative order — a stable, enforceable instrument, not a proposed rule subject to years of revision.

For a whitening product to enter the US market under the OTC monograph pathway, the importer must confirm:

The active ingredient — typically hydrogen peroxide — is permitted under the applicable monograph at the stated concentration
Product labeling conforms exactly to monograph-required language, including directions, warnings, and indications
The manufacturing facility is registered with FDA and the specific product is listed in FDA's drug listing system
Manufacturing is conducted under 21 CFR Part 211, the current GMP regulation for finished pharmaceuticals

FDA is explicit: imported OTC drugs must meet the same registration, listing, and marketing requirements as domestically manufactured products. There is no reduced standard for imported goods. A shipment arriving without proper establishment registration or drug listing on file is subject to refusal of admission.

EU CPNP Registration: Notification Steps and Responsible Person Requirements

The EU pathway operates on a pre-market notification model — not a drug approval or monograph compliance model. Before a cosmetic whitening product can be placed on any EU market, it must be notified through the CPNP, the online portal managed by the European Commission. The notification must be submitted by, or on behalf of, a Responsible Person (RP): a legal entity established within the EU who bears full regulatory accountability for the product.

For importers bringing products into the EU from outside the bloc, appointing a qualified RP is the first operational step — not the last. The RP must be in place before notification is submitted and before any product reaches market. This is a structural difference from the US system, where the importer often holds registration directly.

The CPNP notification requires submission of:

Product category and function
Product name and country of origin
Frame formulation or full ingredient list in INCI nomenclature
Responsible Person name and contact details
Nanomaterial disclosure, if applicable
Original product label and any translations required for target member states

Separately, the RP must maintain a Product Information File (PIF) that includes a cosmetic product safety report, a manufacturing method description, proof of claimed effects, and animal testing status documentation. The PIF is not submitted to the CPNP, but it must be available for inspection by national competent authorities on request.

For whitening products containing hydrogen peroxide above 0.1% and up to 6%, EU Regulation 1223/2009 Annex III restricts the first cycle of use to dental professionals. This supply-chain and labeling constraint must be reflected in both the CPNP notification and the PIF — and it has direct implications for how you structure your distribution agreements within the EU.

GMP Requirements Side by Side: 21 CFR Part 211 vs ISO 22716

Supplier qualification decisions become consequential here. The two markets require compliance with different GMP frameworks, and a facility certified to one standard is not automatically compliant with the other.

Requirement Area	US: 21 CFR Part 211	EU: ISO 22716
Regulatory basis	Federal regulation — mandatory for OTC drug manufacture	International standard referenced in EU Cosmetics Regulation
Scope	Finished pharmaceutical manufacturing	Cosmetic product manufacturing
Batch records	Mandatory, detailed, retained per regulation	Required; format flexible within standard
Laboratory controls	Extensive in-process and finished product testing	Quality control testing per defined specifications
Personnel qualifications	Defined by regulation, including qualified person roles	Competence-based, with documented training required
Facility registration	FDA establishment registration required pre-import	No EU-level facility registration; RP accountability applies
Inspection authority	FDA may inspect domestic or foreign facilities	National competent authorities; no pre-market facility inspection

A supplier producing whitening gel for both markets needs to operate under 21 CFR Part 211 for the US OTC line and ISO 22716 for the EU cosmetic line — and maintain documentation satisfying both frameworks simultaneously. When evaluating a co-developed private-label program, ask specifically which GMP framework applies to each SKU, and request the relevant compliance certificates or third-party audit reports before committing to production volume.

Import Documentation Checklist: US vs EU

Documentation gaps are the most common cause of customs delays and FDA refusals for whitening product importers. The following reflects core filing requirements for each market.

US Market — FDA OTC Monograph Pathway

FDA Establishment Registration — the manufacturing facility must be registered with FDA prior to import
Drug Listing with NDC assignment — the specific product must be listed in FDA's drug listing system with accurate, current labeling and marketing status
Monograph Conformance Documentation — internal records demonstrating active ingredient identity, concentration, and labeling compliance with the applicable OTC monograph
Certificate of Analysis (CoA) — per-batch testing confirming active ingredient concentration and absence of prohibited substances
21 CFR Part 211 GMP Compliance Records — batch records, stability data, and laboratory controls, available for FDA review
US Agent Designation — foreign manufacturers must designate a US agent for FDA communication

EU Market — CPNP Cosmetic Pathway

CPNP Notification — submitted by the Responsible Person before any product reaches the market
Responsible Person Appointment — documented agreement with an EU-established RP prior to notification
Product Information File (PIF) — maintained by the RP; includes safety report, formulation data, and manufacturing description
Cosmetic Product Safety Report (CPSR) — prepared by a qualified safety assessor; required component of the PIF
INCI-Compliant Ingredient Labeling — all ingredients listed in INCI nomenclature in descending order of weight
Annex III Compliance Documentation — for hydrogen peroxide concentrations above 0.1%, evidence that professional-use restrictions are enforced at the distribution level
ISO 22716 GMP Records — maintained and available for national authority inspection

Where Importers Most Often Stall

On the US side, the most frequent stall point is the gap between establishment registration and drug listing. A facility may be registered, but if the specific product SKU is not listed — or if the listing reflects outdated labeling — FDA can refuse the shipment. This is especially common when importers switch suppliers mid-cycle and the new facility has not yet completed its own registration and listing process.

On the EU side, the most common stall is an incomplete or premature RP arrangement. Importers sometimes attempt CPNP notification before a compliant RP agreement is in place, or appoint an RP who lacks the technical capacity to maintain the PIF. When national authorities request the PIF and it is incomplete or the safety report is absent, the product can be pulled from the market — often after it has already entered distribution.

A practical safeguard: before placing any purchase order for a new whitening SKU, confirm in writing that your supplier can provide the FDA establishment registration number (for US) or evidence of an active CPNP notification (for EU). For private-label programs, confirm who holds the drug listing or CPNP notification — and what happens to that registration if you transition to a new supplier.

Choosing a Supplier That Supports FDA CPNP Whitening Import Compliance Across Both Markets

Serving both the US OTC drug channel and the EU cosmetic channel from a single supply relationship is a meaningful operational advantage. It reduces the number of GMP audits you must manage, simplifies CoA and documentation workflows, and allows a private-label whitening line to scale across multiple regulatory territories without rebuilding the compliance stack from scratch.

When evaluating a supplier for a co-developed whitening program, the qualifying questions are specific. Does the facility hold active FDA establishment registration? Is it audited to 21 CFR Part 211 for OTC production and ISO 22716 for cosmetic production? Can it provide batch records and stability data in the format each market requires? Does it have documented experience supporting importers through the drug listing process in the US and through Responsible Person and CPNP notification workflows in the EU?

These are not premium requests — they are baseline qualifications for any supplier entering the professional whitening trade. Private-label programs that are built on documented compliance from the outset protect your brand, your distribution relationships, and your ability to scale.

For buyers evaluating private-label ready whitening formulations with dual-market compliance documentation, WhiteningBright's product range is engineered to support both US OTC and EU cosmetic distribution channels.

References

Disclaimer

This article is for general informational purposes only and does not constitute sourcing, legal, or regulatory advice. Always conduct your own due diligence and consult qualified legal or compliance professionals before making purchasing or compliance decisions. WhiteningBright makes no warranties as to the completeness or accuracy of the information, and any reliance is at your own risk.